Ron Cooper, Albireo CEO

Al­bireo just ad­vanced down to the 10-yard line at the FDA. And Ron Coop­er’s team is get­ting prepped for the next big play

When Al­bireo Phar­ma’s board $AL­BO moved to bring in Ron Coop­er as the CEO more than 5 years ago, the de­vel­op­ment-stage com­pa­ny went with an ex­pe­ri­enced com­mer­cial play­er who had a big-time po­si­tion on his re­sume af­ter run­ning Bris­tol My­ers’ com­mer­cial ops in Eu­rope.

Now, af­ter suc­cess­ful­ly nav­i­gat­ing a piv­otal study, putting them in a foot race with a ri­val to­ward an FDA OK, Coop­er is get­ting a boost from reg­u­la­tors on the last dri­ve back to an are­na he un­der­stands com­plete­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.